Bronchoscopy/BAL for Asthma, Allergic

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Asthma, AllergicBronchoscopy/BAL - Procedure
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying how well memory T helper type 2 cells work to initiate a recall response to aeroallergens in the lungs.

Eligible Conditions
  • Asthma, Allergic

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: This is a single time point study with all information obtained at the time of bronchoscopy defined as Day 0.

Day 0
The phenotype of Th2-Trm recovered from the airway mucosa
The transcriptional profile of Th2-Trm recovered from the airway mucosa

Trial Safety

Trial Design

1 Treatment Group

Allergic Asthmatic or Healthy Control Adults
1 of 1

Experimental Treatment

120 Total Participants · 1 Treatment Group

Primary Treatment: Bronchoscopy/BAL · No Placebo Group · N/A

Allergic Asthmatic or Healthy Control AdultsExperimental Group · 2 Interventions: Bronchoscopy/BAL, Airway Brushing · Intervention Types: Procedure, Procedure

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: this is a single time point study with all information obtained at the time of bronchoscopy defined as day 0.

Who is running the clinical trial?

Andrew D. Luster, M.D.,Ph.D.Lead Sponsor
2 Previous Clinical Trials
211 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,154 Previous Clinical Trials
4,771,264 Total Patients Enrolled
Andrew D LusterPrincipal InvestigatorMGH

Eligibility Criteria

Age 18 - 55 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
All subjects will have a baseline FEV1 of at least 75% of the predicted value.
may be appropriate for treatment with fluticasone furoate/vilanterol People with mild intermittent or mild persistent asthma who are not taking regular daily inhaled corticosteroids may be appropriate for treatment with fluticasone furoate/vilanterol.
People who have asthma that is moderate and persistent (consistent with the treatment options in NAEP Step 3) and who are taking regular daily inhaled corticosteroids (ICS) will have a limit of 220 MCG twice daily of fluticasone or equivalent ICS at screening.
Never having smoked cigarettes throughout your life (total of less than 5 packs of cigarettes smoked and none in the past 5 years).
The person is able to understand the information given to them about the procedure, and is willing to give consent.
Said that he wanted to participate in an interview with the researcher.
People between the ages of 18 and 55.
Subjects who have a PC20 < 16 mg/ml after a methacholine challenge will have a positive challenge.